相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Delayed presentation of HIV among older individuals: a growing problem
Amy C. Justice et al.
LANCET HIV (2022)
The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis
Negin Farhadian et al.
SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY (2022)
Re-assessing the late HIV diagnosis surveillance definition in the era of increased and frequent testing
Peter D. Kirwan et al.
HIV MEDICINE (2022)
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study
Raquel Martin-Iguacel et al.
ECLINICALMEDICINE (2022)
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort
Arturo Ciccullo et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Determinants of HIV-1 Late Presentation in a Cohort of Portuguese HIV-1 Patients
Ana Claudia Miranda et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naive HIV-infected patients starting antiretroviral therapy
Roberta Gagliardini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
Mohamed N'dongo Sangare et al.
MEDICINE (2020)
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting
Antonella d'Arminio Monforte et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study
Marc-Antoine Valantin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Is the rate of virological failure to cART continuing to decline in recent calendar years?
Stefano Rusconi et al.
JOURNAL OF CLINICAL VIROLOGY (2019)
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort
Annalisa Mondi et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2019)
Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients
Pilar Vizcarra et al.
ANTIVIRAL THERAPY (2019)
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data
Amedeo Ferdinando Capetti et al.
ANNALS OF PHARMACOTHERAPY (2018)
Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study
Giovanni Guaraldi et al.
AIDS RESEARCH AND THERAPY (2017)
Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection
Denise C. Hsu et al.
DRUGS (2016)
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
Antonio Di Biagio et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Paz Sobrino-Vegas et al.
JOURNAL OF INFECTION (2016)
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Adam Trickey et al.
PLOS ONE (2016)
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+T-Cell Counts >200+/μl Despite Effective HAART
Giuseppe Lapadula et al.
PLOS ONE (2015)
Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation
Claudie Laprise et al.
CLINICAL INFECTIOUS DISEASES (2013)
Risk Factors for Hospitalization and Medical Intensive Care Unit (MICU) Admission Among HIV-Infected Veterans
Kathleen M. Akguen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis
Amy C. Justice et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
Amanda Mocroft et al.
PLOS MEDICINE (2013)
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis
Olawale Ajose et al.
AIDS (2012)
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome
Antonella d'Arminio Monforte et al.
ANTIVIRAL THERAPY (2011)
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
L. Waters et al.
HIV MEDICINE (2011)
Late presentation of HIV infection: a consensus definition
A. Antinori et al.
HIV MEDICINE (2011)
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*
J. Reekie et al.
HIV MEDICINE (2010)
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe
Amanda Mocroft et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression
Mona R. Loutfy et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries
Mar Pujades-Rodriguez et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
Sean Emery et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
CA Sabin et al.
AIDS (2004)
分享论文
